A1,
A2,
B,
C1,
C2,
D,
E,
F,
G-H,
I-K,
L,
M,
N,
O,
P1,
P2,
Q-R,
S,
T,
U-V,
W-Z
Betopic S Side Effects, and Drug Interactions - Betaxolol HCl
Betopic S Side Effects, and Drug Interactions - Betaxolol HCl
SIDE EFFECTS
Ocular
In clinical trials, the most frequent event associated with the use of
BETOPTIC S Ophthalmic Suspension 0.25% has been transient ocular discomfort.
The following other conditions have been reported in small numbers of
patients: blurred vision, coronal punctate keratitis, foreign body sensation,
photophobia, tearing, itching, dryness of eyes, erythema, inflammation,
discharge, ocular pain, decreased visual acuity and crusty lashes.
Additional medical events reported with other formulations of betaxolol
include allergic reactions, decreased corneal sensitivity, corneal punctate
staining which may appear in dendritic formations, edema and anisocoria.
Systemic
Systemic reactions following administration of BETOPTIC S Ophthalmic
Suspension 0.25% or BETOPTIC Ophthalmic Solution 0.5% have been rarely
reported. These include:
Cardiovascular: Bradycardia, heart block and congestive failure.
Pulmonary: Pulmonary distress characterized by dyspnea. bronchospasm,
thickened bronchial secretions, asthma and respiratory failure.
Central Nervous System: Insomnia, dizziness, vertigo, headaches,
depression, lethargy, and increase in signs and symptoms of myasthenia
gravis.
Other: Hives, toxic epidermal necrolysis, hair loss, and glossitis.
Perversions of taste and smell have been reported.
DRUG INTERACTIONS
Patients who are receiving a beta-adrenergic blocking agent orally and
BETOPTIC S Ophthalmic Suspension 0.25% should be observed for a potential
additive effect either on the intraocular pressure or on the known systemic
effects of betablockade.
Close observation of the patient is recommended when a beta blocker is
administered to patients receiving catecholamine-depleting drugs such
as reserpine, because of possible additive effects and the production
of hypotension and/or bradycardia.
Betaxolol is anadrenergic blocking agent; therefore, caution should be
exercised in patients using concomitant adrenergic psychotropic drugs.
top
